Stanilov N, Grigorova A, Velikova T, Stanilova SA. Genetic variation of TGF-ΒR2 as a protective genotype for the development of colorectal cancer in men. World J Gastrointest Oncol 2021; 13(11): 1766-1780 [PMID: 34853649 DOI: 10.4251/wjgo.v13.i11.1766]
Corresponding Author of This Article
Tsvetelina Velikova, MD, PhD, Assistant Professor, Department of Clinical Immunology, University Hospital Lozenetz, Kozyak 1, Sofia 1407, Bulgaria. tsvelikova@medfac.mu-sofia.bg
Research Domain of This Article
Oncology
Article-Type of This Article
Case Control Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1766-1780 Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1766
Table 1 Difference in genotype distribution and allele frequencies of TGFBR2 rs3087465 polymorphism between the case (colorectal cancer patients) and control (healthy persons) groups, females and males, respectively
Genotype
CRC, n (%)
Healthy controls, n (%)
OR (95%CI)
P value
n
184 (100)
307 (100)
GG
117 (63.6)
193 (62.9)
Reference
GA
58 (31.5)
102 (33.2)
0.938 (0.631-1.393)
0.751
AA
9 (4.9)
12 (3.9)
1.237 (0.506-3.026)
0.640
GA + AA
67 (36.4)
114
0.969 (0.664-1.416)
0.873
G allele
292 (79.3)
488 (79.5)
Reference
A allele
76 (20.7)
126 (20.5)
1.008 (0.732-1.387)
0.961
Female
69
240
GG
42 (40.9)
159 (66.3)
Reference
GA
22 (31.9)
72 (30)
1.157 (0.664-2.079)
0.626
AA
5 (7.2)
9 (3.7)
2.103 (0.669-6.608)
0.195
GA + AA
27(39.1)
81 (33.8)
1.262 (0.726-2.193)
0.409
GG vs GA + AA
42 vs 27
159 vs 81
0.792 (0.456-1.377)
0.409
GA vs GG + AA
22 vs 47
72 vs 168
1.092 (0.614-1.944)
0.764
G allele
106 (76.8)
390 (81.3)
Reference
A allele
32 (23.2)
90 (18.7)
1.346 (0.794-2.281)
0.269
Male
115
67
GG
75 (65.2)
34 (50.7)
Reference
GA
36 (31.3)
30 (44.8)
0.544 (0.289-1.023)
0.058
AA
4 (3.5)
3 (4.5)
0.604 (0.128-2.850)
0.521
c 0.823
GA + AA
40 (34.8)
33 (49.3)
0.549 (0.297-1.015)
0.055
GG vs GA + AA
75 vs 40
34 vs 33
1.820 (0.985-3.362)
0.055
GA vs GG + AA
36 vs 79
30 vs 37
0.562 (0.302-1.047)
0.068
G allele
186 (80.9)
98 (73.1)
Reference
A allele
44 (19.1)
36 (26.9)
0.644 (0.389-1.066)
0.086
Table 2 Genotype distributions and allele frequencies of TGFBR2 rs3087465 polymorphism in the case group divided into advanced and early colorectal cancer groups (and females and males, respectively)
TGFBR2 -875G/A (rs3087465)
Advanced CRC, n (%)
Early CRC, n (%)
OR (95%CI)
P value
Total n
96 (52.2)
88 (47.8)
GG
64 (66.7)
53 (60.2)
Reference
GA
29 (30.2)
29 (33)
0.828 (0.441-1.556)
0.557
AA
3 (3.1)
6 (6.8)
0.414 (0.099-1.735)
0.216
c 0.373
GA + AA
32 (33.3)
35 (39.8)
0.757 (0.415-1.382)
0.365
G allele
157 (81.8)
135 (76.7)
Reference
A allele
35 (18.2)
41 (23.3)
0.734 (0.442-1.218)
0.230
Female
35 (36.5)
34 (38.6)
GG
22 (62.9)
20 (58.8)
Reference
GA
12 (34.3)
10 (29.4)
1.091 (0.388-3.071)
0.869
AA
1 (2.9)
4 (11.8)
0.227 (0.023-2.207)
0.171
c 0.370
GA + AA
13 (37.1)
14 (41.2)
0.844 (0.321-2.222)
0.731
G allele
56 (80)
50 (73.5)
Reference
A allele
14 (20)
18 (26.5)
0.694 (0.313-1.539)
0.368
Male
61 (63.5)
54 (61.4)
GG
42 (68.9)
33 (61.1)
Reference
GA
17 (27.9)
19 (35.2)
0.703 (0.317-1.561)
0.386
AA
2 (3.3)
2 (3.7)
0.786 (0.105-5.878)
0.814
c 1.000
GA + AA
19 (31.1)
21 (38.9)
0.711 (0.329÷1.535)
0.384
GG vs GA + AA
42 vs 19
33 vs 21
1.407 (0.651-3.038)
0.384
G allele
101 (82.8)
85 (78.7)
Reference
A allele
21 (17.2)
23 (21.3)
0.768 (0.398÷1.484)
0.432
Table 3 TGFBR2G[-875]A rs3087465 polymorphism distribution in early CRC cases compared to healthy controls
TGFBR2 -875G/A (rs3087465)
Early CRC, n (%)
Healthy controls, n (%)
OR (95%CI)
P value
Total n
88 (47.8)
307 (100)
GG
53 (60.2)
193 (62.9)
Reference
GA
29 (33)
102 (33.2)
1.035 (0.620-1.728)
0.894
AA
6 (6.8)
12 (3.9)
1.821 (0.653-5.080)
0.246
GA + AA
35 (39.8)
114
1.118 (0.688-1.817)
0.652
G allele
135 (76.7)
488 (79.5)
Reference
A allele
41 (23.3)
126 (20.5)
1.176 (0.788-1.756)
0.427
Female
34 (38.6)
240
GG
20 (58.8)
159 (66.3)
Reference
GA
10 (29.4)
72 (30)
1.104 (0.492-2.478)
0.810
AA
4 (11.8)
9 (3.7)
3.533 (0.996-12.535)
0.039
c 0.103
GA + AA
14 (41.2)
81 (33.8)
1.374 (0.660-2.861)
0.394
G allele
50 (73.5)
390 (81.3)
Reference
A allele
18 (26.5)
90 (18.7)
1.560 (0.869-2.802)
0.134
Male
54 (61.4)
67
GG
33 (61.1)
34 (50.7)
Reference
GA
19 (35.2)
30 (44.8)
0.653 (0.309-1.379)
0.262
AA
2 (3.7)
3 (4.5)
0.687 (0.108-4.378)
0.690
c 1.000
GA + AA
21 (38.9)
33 (49.3)
0.656 (0.317-1.357)
0.254
GG vs GA + AA
33 vs 21
34 vs 33
1.525 (0.737-3.156)
0.254
G allele
85 (78.7)
98 (73.1)
Reference
A allele
23 (21.3)
36 (26.9)
0.737 (0.405-1.340)
0.316
Table 4 TGFBR2G[-875]A rs3087465 polymorphism distribution in advanced CRC cases compared to healthy controls
TGFBR2 -875G/A (rs3087465)
Advanced CRC, n (%)
Healthy controls, n (%)
OR (95%CI)
P value
Total n
96 (52.2)
307 (100)
GG
64 (66.7)
193 (62.9)
Reference
GA
29 (30.2)
102 (33.2)
0.857 (0.520-1.414)
0.546
AA
3 (3.1)
12(3.9)
0.754 (0.206-2.756)
0.668
c 0.940
GA + AA
32 (33.3)
114
0.846 (0.522-1.373)
0.499
GA vs GG + AA
29 vs 67
102 vs 205
0.870 (0.530-1.429)
0.582
G allele
157 (81.8)
488 (79.5)
Reference
A allele
35 (18.2)
126 (20.5)
0.863 (0.570÷1.308)
0.488
Female
35 (36.5)
240
GG
22 (62.9)
159 (66.3)
Reference
GA
12 (34.3)
72 (30)
1.205 (0.565-2.567)
0.629
AA
1 (2.9)
9 (3.7)
0.803 (0.097-6.647)
0.839
c 1.000
GA + AA
13 (37.1)
81 (33.8)
1.160 (0.556-2.421)
0.693
G allele
56 (80)
390 (81.3)
Reference
A allele
14 (20)
90 (18.7)
1.083 (0.578-2.032)
0.803
Male
61 (63.5)
67
GG
42 (68.9)
34 (50.7)
Reference
GA
17 (27.9)
30 (44.8)
0.459 (0.217-0.969)
0.039
AA
2 (3.3)
3 (4.5)
0.540 (0.085-3.417)
0.507
c 0.841
GA + AA
19 (31.1)
33 (49.3)
0.466 (0.226-0.961)
0.037
GG vs GA + AA
42 vs 19
34 vs 33
2.146 (1.041-4.422)
0.037
GA vs GG + AA
17 vs 44
30 vs 37
0.477 (0.228-0.997)
0.047
G allele
101 (82.8)
98 (73.1)
Reference
A allele
21 (17.2)
36 (26.9)
0.566 (0.309-1.037)
0.064
Citation: Stanilov N, Grigorova A, Velikova T, Stanilova SA. Genetic variation of TGF-ΒR2 as a protective genotype for the development of colorectal cancer in men. World J Gastrointest Oncol 2021; 13(11): 1766-1780